• Shoko Okahara, Tetsuya Handoh, Mitsuru Wakita, Takamasa Yamamoto, Shigeki Misawa, Takashi Miida, and Hiroyuki Sumikura.
• Department of Anesthesiology, Juntendo University Hospital, 3-1-3 Hongo Bunkyo-ku, Tokyo, 113-8431, Japan.
• J Anesth. 2021 Oct 1; 35 (5): 757-760.

AbstractTimely fibrinogen replacement is key to treating critical hemorrhage. Measuring fibrinogen concentration by conventional laboratory tests requires centrifugation of blood samples and is often time-consuming. A point-of-care testing device (A&T, Yokohama, Japan), CG02N, has been available in Japan since 2011 to measure fibrinogen concentration without centrifugation. However, it has not been widely used as it requires dilution of blood samples using manual micropipetting. To further speed up and simplify the fibrinogen measurement, an improved device called FibCare (Atom Medical, Tokyo, Japan) was developed to avoid diluting blood samples. The purpose of this study is to verify the reliability of FibCare against laboratory measurement using the Clauss method. Fibrinogen concentrations with 60 sodium citrated whole blood samples were measured by both FibCare and Clauss methods in the laboratory. Measured values with the Clauss method were distributed in the 88-300 mg/dL range. By comparing these results, a significant positive correlation was observed between the FibCare and Clauss method (Y = 12.402 + 0.982 X; R = 0.891; P < 0.01). The study indicated that FibCare allows accurate measurement of fibrinogen concentration and shows a possibility to contribute to optimal fibrinogen replacement therapy during critical hemorrhage.© 2021. Japanese Society of Anesthesiologists.

10 keywords...

hide…